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Abstract: The efficacy of the intranasally (i.n.) delivered live attenuated influenza vaccine (LAIV) is
variable and, in some seasons, suboptimal. In this study, we report that LAIV exhibits cross-protective
efficacy in mice, potentially associated with cellular immunity as opposed to antigen-specific antibody
responses. However, pre-exposure to the intramuscularly (i.m.) delivered inactivated influenza
vaccine (IIV) severely impaired LAIV-induced cross-protection against heterologous challenge,
potentially by inhibiting replication of LAIV. Our findings suggest that pre-existing immunity
afforded by IIV suppresses cross-protective T cell immunogenicity of LAIV.
Keywords: influenza; pre-existing immunity; live attenuated influenza vaccine; inactivated
influenza vaccine
1. Introduction
The current quadrivalent influenza vaccines contain antigens derived from four influenza viruses
of subtypes A and B. These vaccines are mainly either inactivated influenza vaccines (IIVs) (including
subunit or split-virion), live attenuated influenza vaccines (LAIVs) or recombinant hemagglutinin
(HA) vaccines. Compared to IIV, which predominantly induces strain-specific neutralizing antibody
responses, LAIV elicits broad immune responses, including cellular as well as humoral immunity.
In experimental animal challenge models of influenza, LAIV consistently elicited superior protective
immune responses compared to IIV [1,2], including cross-protective immunity [3]. However, the use
of LAIV in infants has been reported to cause wheezing and increased hospitalizations, resulting in
recommendation against the use of LAIV in children below the age of 2 years [4]. Therefore, according to
the Centers for Disease Control and Prevention’s (CDC) recommended influenza vaccination schedule,
most children (age < 2) in the U.S. are exposed to IIV via parenteral route. LAIVs, which are available
for individuals 2–49 years of age, will likely be administered to individuals who have previously been
vaccinated with parenteral IIV. LAIV, or “flumist”, was withdrawn from the market during 2016–2017
and 2017–2018 influenza seasons because a meta-analysis of combined observational studies from
2013 to 2016 reported reduced effectiveness of LAIV against H1N1 influenza virus [5–7]. The clinical
report on inferior efficacy of LAIV compared to IIV was in striking contrast to those findings made in
animal models across several studies where LAIV was shown to be superior [1–3,5]. The discrepancies
in LAIV efficacy between animal models and humans raise a question about the predictive value
of animal models used for influenza vaccine research, especially if the vaccination context between
animal studies and the clinic vary significantly.
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Numerous animal and human studies have assessed the role of pre-existing immunity to influenza
on subsequent influenza vaccine efficacy [8,9], specifically, the impact of pre-existing immunity on
subsequent IIV vaccination. For example, Kim et al. demonstrated that prior influenza infection can
enhance the efficacy of subsequent split IIV against drifted strains [9]. However, little is known about the
impact of prior vaccination with IIV on LAIV efficacy. Using an infection mouse model, Bodewes et al.
showed that prior IIV-derived immunity limits replication of an incoming virus, mitigating protective
influenza-specific memory Interferon-gamma (IFN-γ)+ CD8+ T cell responses induced by heterologous
influenza infection [10]. Nevertheless, in animal models, the impact of prior exposure to influenza
antigens on LAIV efficacy is often not tested. Thus, we established a mouse model wherein mice were
sequentially vaccinated with IIV vaccine followed by LAIV to evaluate if pre-existing immunity can
detrimentally impact the efficacy of LAIV. Our sequential vaccinations/infection model shows that
pre-existing immunity established by the IIV vaccination suppresses cross-protective efficacy of LAIV,
a finding that has important implications for evaluating experimental universal influenza vaccines in
animal models. This work may help design better mouse models of influenza to increase the predictive
value for vaccine evaluation.
2. Materials and Methods
2.1. Immunisation and Challenge
Seven–eight-week-old BALB/c mice were purchased from Charles River Laboratories. Due to the
lack of expression of functional M× 1 protein, in-bred laboratory generated BALB/c mice are susceptible
to influenza infection. Consequently, these mice have been commonly used for evaluation of influenza
vaccine efficacy [11]. Mice were maintained in the Animal Research Facility at Albany Medical College,
and all procedures were approved by the Institutional Animal Care and Use Committee. Mice were
immunized as indicated in Figure 1a with either 1.5 µg of IIV Fluzone quadrivalent vaccine (2015–2016
formulation, Sanofi Pasteur, Lyon, France) intramuscularly (i.m.) and/or 5 × 107 plaque forming units
(PFU) of LAIV Flumist quadrivalent 2015–2016 vaccine (2015–2016 formulation, MedImmune, MA,
USA) intranasally (i.n.). Mice were challenged i.n. with either 5 × 103 PFU of homologous H1N1
CA/04/2009 (CA04) virus or heterologous H1N1 A/PR/8/1934 (PR8) virus. Following challenge, mice
were monitored for survival and weight loss for 20 days without anesthesia.
2.2. Hemagglutination Inhibition (HI) Assay
Serially diluted mouse serum was mixed with either 4 HA units of CA04 virus or 4 HA units of
PR8 virus in V bottom 96-well plates. After 30 min incubation, 0.5% of chicken red blood cells (Lampire
Biological Laboratories, Pipersville, PA, USA) were added and incubated for an additional 1 h at room
temperature. The HI titer was defined as the reciprocal of the highest dilution that prevented viral
hemagglutination activity.
2.3. Statistical Analysis
GraphPad Prism 7 software was used for statistical analyses. Survival data were analyzed by the
Mantel–Cox log-rank test. HI titers were analyzed by either a paired t test or two-way ANOVA followed
by Sidak’s multiple comparison test. p values of <0.05 were considered to be statistically significant.
3. Results
3.1. IIV-Derived Pre-Existing Immunity Inhibits LAIV-Induced Cross-Protection
To investigate the impact of pre-existing immunity on LAIV efficacy, mice were first i.m. vaccinated
with IIV or PBS and then i.n. immunized with LAIV or PBS (Figure 1a). Following vaccination, mice
were challenged with homologous CA04 and monitored for survival and weight loss for 20 days.
The mock vaccinated mice showed rapid decrease in survival (survival percentage 25%) and a maximum
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weight loss by day 9 post challenge (Figure 1b,c). In contrast, mice vaccinated with either IIV or LAIV
alone, or a combination of IIV and LAIV, showed 100% survival and prevented significant weight loss
following homologous challenge with the CA04 virus (Figure 1b,c).
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3.2. IIV Does Not Impact Subsequent LAIV-Elicited Cross-Protective Hemagglutinin Inhibition (HI) Titers
Next, to assess the impact of prior IIV vaccination on LAIV-induced influenza-specific
cross-protective antibody responses, cross-reactive serum antibodies were measured by HI assay.
Mice were immunized with i.m. IIV, i.n. LAIV or combination of both as described in Figure 2a.
Anti-CA04 and Anti-PR8 HI titers were measured 3 weeks after the last vaccination. Data revealed
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that regardless of vaccination regimen, all vaccinated mice induced significant HI titer against the
homologous strain CA04 (Figure 2b,c). In contrast, HI titers against the heterologous PR8 strain were
not detected (Figure 2b,c). Thus, while LAIV is capable of providing cross-protection against PR8 virus,




Figure 2. Evaluating the impact of prior IIV on LAIV-induced homologous and heterologous
virus-specific antibody titers. (a) BALB/c mice were either i.m. PBS treated (control) or vaccinated
with each vaccine (i.m. IIV or i.n. LAIV) alone or in combination. Serum harvested on either (b)
week 3 (n = 16 per group) or (c) week 6 (n = 4–8 per group) as indicated was analyzed for anti-CA04 or
anti-PR8 haemagglutinin inhibition (HI titers) as described in Section 2. Error bars represent standard
deviation (SD), and p values were calculated using paired t test (left) and two-way ANOVA followed
by Sidak’s multiple comparison test (right). *** p < 0.001, **** p < 0.0001.
4. Discussion
The current study demonstrates that prior IIV vaccination does not negatively impact strain-specific
immunity induced by LAIV. However, prior IIV vaccination had a detrimental impact on cross-protective
immunity elicited by LAIV against heterologous PR8 influenza infection. We speculate that prior
IIV vaccination suppresses T cell immunogenicity of LAIV since the observed cross-protection in
LAIV-only-vaccinated mice did not correlate with HI titers, indicating an important role of cell-mediated
immunity in providing cross-protection. This is unsurprising since numerous mouse studies, including
ours have shown the critical role of T cells in mediating cross-protection against influenza [12].
Moreover, LAIV has also been shown to afford cross-protection via cell-mediated immunity [13,14].
Therefore, it is likely that the observed cross-protection in LAIV-only-vaccinated mice is due to the
cross-reactive T cells and that prior vaccination with IIV interferes with establishment of LAIV-induced
T cell immunity.
One of the major reasons speculated for suboptimal LAIV vaccine efficacy against H1N1 strains is
the reduced replicative capacity of vaccine H1N1 pdm09-like strains (A/California/7/2009 for 2013–2014
and A/Bolivia/559/2013 for 2015–2016) in human nasal cells. Replacement of the antigen formulation
of LAIV in a subsequent influenza season with H1N1 pdm09-like virus A/Slovenia/2903/2015, which
has a better replicative fitness, has indeed improved LAIV-elicited vaccine immunity [15]. Thus,
we speculate that the reduced efficacy of LAIV in our mouse model is due to the pre-existing
neutralizing antibodies interfering with LAIV replication. Consistent with our hypothesis, a recent
phase II clinical trial of a Russian backbone LAIV in Bangladesh has reported that the magnitude of
LAIV-induced humoral responses were associated with detectable vaccine virus shedding in vaccine
Vaccines 2020, 8, 459 5 of 6
recipients [8]. It was also found that the vaccine recipients with lower pre-existing immunity had
higher odds of viral shedding after vaccination. Thus, the vaccine viral infectivity is likely to be a key
determinant of vaccine effectiveness. This is a particularly important factor for T cell immunity as
in vivo antigen generation and antigen presentation via major histocompatibility complex (MHC)-I
is required to prime cytotoxic T cells. Studies have evidenced that prior vaccination suppresses
memory IFN-γ+ CD8 T cell responses induced by subsequent viral infection [10]. Therefore, taken
together, our studies suggest that the pre-existing immunity, which was established by the prior i.m.
IIV vaccination, reduced LAIV T cell immunogenicity by limiting LAIV viral replication. Our finding
that the pre-existing immunity negatively impacts cross-protective immunity against heterologous
PR8, but not strain-specific immunity, has implications for universal flu vaccine development. First,
the cross-protective efficacy of an experimental universal flu vaccine should be evaluated in the
presence of pre-existing immunity for influenza in animal models, as most humans do have some
level of immunity against influenza through seasonal vaccinations and/or exposures to circulating
influenza strains. Second, a universal flu vaccine based on live virus or vectors need to consider the
infectivity of vaccine strains in the presence of pre-existing immunity. This is particularly a concern
for T cell dependent vaccines since pre-existing immunity is more likely to negatively impact T cell,
but not humoral, immunogenicity of vaccines. Therefore, third, the mechanism of vaccine mediated
cross-protection, which is largely dictated by the vaccine type, becomes critical because pre-existing
immunity is likely to have differential impact on humoral vs. cellular immunity. Lastly, the choice of
population group needs careful consideration because the magnitude of pre-existing immunity will
vary based on age group with very young children expected to have low natural immunity. Thus,
in our mouse model, we predict that if LAIV is administered prior to IIV, then cross-protection will
be observed.
5. Conclusions
In conclusion, this study highlights that prior IIV vaccination status of a vaccine recipient may be
an important factor that determines the efficacy of a universal influenza vaccine. Our data also clearly
demonstrate that multiple vaccinations with IIV followed by LAIV result in suboptimal heterosubtypic
immunity against heterologous influenza infections.
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